Report Library
All ReportsAcute Lymphocytic Leukemia KOL Interview
February 09, 2016
If you are a KOL Insight Subscriber, please access this report here, in our KOL
Insight portal (Subscribers only).
Highlights
For our disclosures, please read the BioMedTracker Research Standards.
- KOL specializing in stem cell transplants for hematologic malignancies
- ALL is fairly uncommon with a high cure rate, so new therapies must target the relapsed space
- CAR-T therapies will definitely be approved for ALL, but not settled for other B-cell malignancies
- The neurotoxicity associated with CAR-T therapies is unpredictable and variable. The underlying pathophysiology is unknown
- PD-1s are unlikely to be single-agent therapies for heme malignancies and unlikely to be wildly successful in aggressive heme malignancies
For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: | Acute Lymphoblastic Leukemia (ALL) |
Additional Resources: